As a reference centre in the validation of medical devices, in addition to the GLP validation of iVascular and Rob Surgical products and new medical device candidates in the portfolio, CMCiB has positioned itself over the years as a reference centre in the territory for the validation of new and complex technologies.

Recently, an important early-phase multicentric clinical study (first-in-human, FIH) for patients with coronary microvascular dysfunction or microvascular angina has been initiated, using an innovative therapy developed by VahatiCor, an international client of the centre specialised in developing medical devices addressing unmet medical needs for cardiac patients. CMCiB has carried out preclinical validation functional studies with the A-FLUX Reducer performed in their state-of-the-art surgical facilities, as well as specialised training for reference clinicians, enabling them to use the new product in people in the planned trials, reaffirming CMCiB's position as a reference centre in the validation of medical devices within various therapeutic areas.

The A-FLUX Reducer, implanted in the coronary sinus -the largest vein of the heart-, has been designed to improve blood flow in ischemic areas of the heart, with the aim of alleviating symptoms and enhancing the quality of life of patients.

This success story demonstrates the capability of new technologies to meet unmet medical needs, by "providing predictable and low-risk treatments for a growing population of patients with angina symptoms who do not achieve satisfactory results with conventional medications or lifestyle changes", as noted by VahatiCor.